List of Excipients in Branded Drug PEXEVA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sebela Pharmaceuticals Inc	PEXEVA	paroxetine mesylate	54766-201	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Sebela Pharmaceuticals Inc	PEXEVA	paroxetine mesylate	54766-201	HYDROXYPROPYL CELLULOSE
Sebela Pharmaceuticals Inc	PEXEVA	paroxetine mesylate	54766-201	HYPROMELLOSE 2910
Sebela Pharmaceuticals Inc	PEXEVA	paroxetine mesylate	54766-201	MAGNESIUM STEARATE

Pexeva Excipient Strategy and Commercial Opportunities for Paroxetine Mesylate

Last updated: August 16, 2026

Pexeva is an immediate-release paroxetine mesylate tablet marketed for major depressive disorder, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and post-traumatic stress disorder. Its commercial value now depends primarily on manufacturing efficiency, generic substitution, formulation differentiation, and lifecycle products rather than brand patent exclusivity. The core excipient opportunity is a low-cost, conventional tablet platform that preserves dissolution, content uniformity, stability, and patient acceptability while supporting multiple strengths.

What is Pexeva and which active ingredient does it contain?

Pexeva contains paroxetine mesylate, a selective serotonin reuptake inhibitor. The product is an oral, immediate-release tablet. Each strength contains a molar equivalent of paroxetine base, with tablets marketed in 10 mg, 20 mg, 30 mg, and 40 mg strengths.[1]

Product attribute	Pexeva profile
Active ingredient	Paroxetine mesylate
Pharmacologic class	Selective serotonin reuptake inhibitor
Dosage form	Immediate-release oral tablet
Strengths	10 mg, 20 mg, 30 mg, 40 mg
FDA application	NDA 21-323
Primary dosage route	Oral
Primary formulation objective	Rapid, reproducible immediate release
Key competitive products	Generic paroxetine hydrochloride and paroxetine mesylate products, Paxil and Paxil CR

Paroxetine mesylate differs chemically from paroxetine hydrochloride, but both deliver paroxetine as the active moiety. This distinction matters for regulatory submissions, salt selection, equivalence strategy, and intellectual-property analysis.

What excipients are used in Pexeva tablets?

Pexeva uses a conventional solid oral formulation architecture. Public labeling identifies inactive ingredients including lactose monohydrate, microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate, hypromellose, polyethylene glycol, polysorbate 80, and titanium dioxide, although exact excipient composition and coating quantities can vary by strength and manufacturing presentation.[1]

The formulation can be divided into four functional groups:

Formulation function	Likely excipient role
Dilution and tablet mass	Lactose monohydrate and microcrystalline cellulose
Binder and granulation aid	Povidone
Disintegration	Sodium starch glycolate
Lubrication	Magnesium stearate
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, and colorant system

The excipient system is commercially conventional. It does not indicate an extended-release mechanism, enteric protection, osmotic delivery system, or complex solubility-enhancement platform.

Why does the Pexeva excipient system matter?

Paroxetine is administered at relatively low-to-moderate tablet strengths, so excipient selection affects dose uniformity and tablet handling more than total tablet mass. The main technical requirements are:

1. Consistent distribution of paroxetine mesylate across the blend.
2. Adequate tablet hardness without delayed disintegration.
3. Low sensitivity to magnesium stearate over-lubrication.
4. Stable film adhesion and appearance.
5. Reliable dissolution across commercial-scale batches.
6. Controlled moisture exposure during granulation, compression, and packaging.

A lactose-cellulose combination provides a familiar platform for direct compression or wet granulation, depending on the target process. Povidone can improve granule strength, while sodium starch glycolate supports rapid tablet breakup. Magnesium stearate reduces tooling friction but must be controlled because excessive lubrication can reduce tablet tensile strength and slow dissolution.

How can manufacturers optimize the Pexeva excipient strategy?

The most defensible strategy is an immediate-release, bioequivalent formulation using widely available compendial excipients. The goal is not to reproduce every inactive ingredient in the reference product. FDA generic drug standards generally permit differences in excipients when the product meets pharmaceutical equivalence, bioequivalence, quality, and labeling requirements.[2]

Direct-compression platform

A direct-compression formulation can reduce processing steps, equipment requirements, and batch-cycle time. It may use:

• Spray-dried lactose or anhydrous lactose for flow and compactability.
• Microcrystalline cellulose for binding and tablet strength.
• Crospovidone or croscarmellose sodium as alternative disintegrants.
• Low-concentration colloidal silicon dioxide for flow control.
• Magnesium stearate or sodium stearyl fumarate as lubricant options.

The commercial advantage is lower manufacturing complexity. The technical risk is segregation because the drug load is modest and paroxetine mesylate may have different particle-size and density characteristics from the excipient blend.

Wet-granulation platform

Wet granulation can improve content uniformity and reduce segregation. Povidone or hypromellose may be used as a binder. The disadvantages are higher processing cost, greater exposure to water or solvent, and additional drying controls.

A wet-granulation process may be preferred when:

• The active has poor flow.
• Direct compression produces unacceptable weight variation.
• Tablet friability is high.
• Dissolution varies with compression force.
• The formulation must tolerate high-volume generic production.

Coating strategy

The film coat has limited therapeutic value but can improve:

• Swallowability.
• Identification by strength.
• Moisture protection.
• Mechanical resistance.
• Brand or portfolio differentiation.

Titanium dioxide and colorants can create regulatory and market-access issues in some jurisdictions. A supplier may gain geographic flexibility by developing both a titanium-dioxide-containing formulation and a compliant alternative using other opacifiers or a lower-pigment coating system.

What formulation patents protect Pexeva?

Pexeva's historical formulation position does not appear to rest on a durable, high-complexity delivery technology. The product is an immediate-release paroxetine mesylate tablet rather than a controlled-release system such as Paxil CR.

The primary intellectual-property distinction is the paroxetine mesylate salt and its pharmaceutical formulation. Historical patent protection associated with paroxetine products included compound, salt, formulation, and use claims. Many of the commercially relevant patents have expired or lost practical blocking value following generic entry.

IP category	Relevance to Pexeva
Paroxetine compound patents	Historically important, now expired
Paroxetine mesylate salt patents	Relevant to salt-specific development and equivalence
Immediate-release tablet patents	Potentially relevant to excipient and process design
Method-of-use patents	Historically relevant to psychiatric indications
Controlled-release patents	More closely associated with Paxil CR than Pexeva
Manufacturing patents	May affect crystallization, particle engineering, or scale-up
Active Orange Book barrier	No durable commercial barrier is expected from the historical Pexeva estate

The commercial question is less whether an excipient combination copies the brand formulation and more whether the proposed formulation infringes any unexpired claim while meeting FDA requirements. Because paroxetine is an established active ingredient, a generic applicant would typically evaluate an abbreviated new drug application pathway rather than pursue a full new-drug program.

When did Pexeva lose exclusivity?

Pexeva no longer has meaningful market exclusivity based on its original approval. The product was approved in 2003, and the relevant small-molecule exclusivity periods have expired.[1,3]

The relevant timeline is:

Event	Timing
Pexeva FDA approval	2003
Five-year new chemical entity exclusivity	Expired
Three-year exclusivity linked to new clinical investigations	Expired
Historical patent term	Expired or no longer commercially blocking
Generic opportunity	Open, subject to product-specific FDA requirements

Pexeva should be analyzed as a mature generic market, not as an originator product with a remaining launch barrier. Current commercial access depends on ANDA approval, manufacturing economics, supply reliability, payer substitution, and channel access.

What is the Orange Book status of Pexeva?

Pexeva is associated with an FDA-approved NDA for paroxetine mesylate tablets. The Orange Book is the authoritative source for listed patents, exclusivity, therapeutic-equivalence evaluations, and reference-listed-drug status.[3]

For business planning, the key Orange Book conclusions are:

• The product's original exclusivity has expired.
• Any remaining listed patent must be reviewed by strength and product presentation.
• A generic applicant must identify the applicable reference-listed drug.
• A Paragraph IV certification is relevant only if an unexpired listed patent remains.
• An ANDA may use Paragraph III or Paragraph IV certifications depending on the patent record at the time of filing.

A generic applicant should not assume that the absence of a major brand barrier eliminates all regulatory work. The applicant still must demonstrate pharmaceutical equivalence, bioequivalence, chemistry and manufacturing controls, stability, and appropriate labeling.

Which companies are challenging Pexeva exclusivity?

Pexeva is already exposed to generic competition. The relevant competitive set includes manufacturers of paroxetine products, including products using paroxetine hydrochloride and paroxetine mesylate. Generic competition may arise from companies with established antidepressant portfolios, contract manufacturers, or suppliers that can leverage existing paroxetine manufacturing capacity.

The competitive field is shaped by:

• ANDA approval status.
• Availability of paroxetine mesylate rather than only paroxetine hydrochloride.
• Manufacturing cost per tablet.
• Ability to supply four strengths.
• Quality history and warning-letter exposure.
• Wholesaler and pharmacy purchasing agreements.
• Reimbursement positioning.

A Paragraph IV challenge is commercially relevant only where the FDA record identifies an unexpired patent that could delay approval. For an old immediate-release product such as Pexeva, the larger risk is often commodity price erosion rather than patent litigation.

What generic entry risks exist for Pexeva?

Generic entry risks are high because the product has an established active ingredient, conventional dosage form, and long clinical history. The main risk categories are operational rather than scientific.

Regulatory risk

Paroxetine has clinically important withdrawal, psychiatric, sexual-function, and drug-interaction considerations. The applicant must maintain accurate labeling and demonstrate that formulation changes do not alter exposure in a clinically meaningful way.[1]

Bioequivalence risk

Immediate-release products still require controlled dissolution and pharmacokinetic performance. Excipient changes may alter:

• Disintegration time.
• Dissolution rate.
• Gastrointestinal release.
• Peak plasma concentration.
• Total exposure.

A formulation that passes routine tablet testing but produces a different dissolution profile can create development delays or additional regulatory scrutiny.

Supply-chain risk

Paroxetine mesylate may have fewer qualified suppliers than common excipients. Supply planning should cover:

• Active pharmaceutical ingredient source qualification.
• Salt-form consistency.
• Particle-size control.
• Residual-solvent specifications.
• Nitrosamine and genotoxic impurity assessment.
• Dual sourcing for critical excipients.

Commercial risk

Multiple generic entrants can rapidly reduce net pricing. A manufacturer needs a cost position that remains viable after wholesaler discounts, pharmacy benefit manager pressure, returns, and potential manufacturing remediation.

What commercial opportunities exist for Pexeva excipients?

The most attractive opportunities are incremental products built on the same immediate-release platform.

Lower-cost generic paroxetine mesylate

A manufacturer can replace relatively expensive excipients with qualified, widely available alternatives while preserving dissolution and bioequivalence. The opportunity is strongest where the product has limited supplier competition or where existing manufacturers have recurring shortages.

Excipient supplier partnerships

Excipient manufacturers can offer prequalified co-processed systems for:

• Low-dose-content uniformity.
• Direct compression.
• Rapid disintegration.
• Low-friability tablets.
• Low-moisture processing.
• Film coating with broad geographic compliance.

A co-processed lactose-cellulose or cellulose-disintegrant system can reduce formulation development time and manufacturing variability.

Flexible global formulation

A global platform can use common core tablets with region-specific coating systems. This approach may address differences in permitted colorants, titanium dioxide policies, labeling, and packaging requirements without creating multiple core formulations.

Patient-friendly dosage forms

Paroxetine has a potential lifecycle opportunity in orally disintegrating tablets, sprinkle formulations, oral liquids, or smaller tablets for patients with swallowing difficulty. These products would require a new regulatory strategy and may face limited commercial demand because generic tablets and other paroxetine dosage forms are already available.

Specialty packaging

Moisture-resistant blister packaging, unit-dose packaging, and calendar packs can improve dispensing control and support institutional or adherence-focused channels. Packaging differentiation is less likely to create durable exclusivity but can support contracting and channel positioning.

How does Pexeva compare with Paxil and Paxil CR?

Pexeva competes mainly with immediate-release paroxetine products. Paxil CR has a different release mechanism and therefore a different formulation and patent profile.

Attribute	Pexeva	Paxil	Paxil CR
Active moiety	Paroxetine	Paroxetine	Paroxetine
Salt/formulation distinction	Paroxetine mesylate immediate-release tablet	Paroxetine hydrochloride immediate-release tablet	Controlled-release formulation
Excipient complexity	Conventional	Conventional	Higher, because release must be controlled
Generic substitution	Mature	Mature	Dependent on controlled-release equivalence
Main formulation challenge	Content uniformity and rapid release	Same	Release profile and pharmacokinetic equivalence
Commercial opportunity	Low-cost supply and differentiated packaging	Broad generic volume	Specialized controlled-release competition

Pexeva has a lower formulation barrier than Paxil CR. That reduces development cost but also limits pricing power.

Does Pexeva have biosimilar risk?

No. Pexeva is a small-molecule drug, not a biologic. Biosimilar regulation does not apply. Competitive products are generics evaluated through ANDA or, for certain differentiated products, other FDA pathways such as 505(b)(2).

The relevant substitution risk is generic paroxetine, not biosimilar paroxetine.

What is the litigation and settlement outlook for Pexeva?

The current commercial litigation risk is expected to be limited relative to newer branded medicines. The original product is old, the dosage form is conventional, and broad market entry has occurred. Historical patent disputes may have involved paroxetine salts, formulations, or related products, but a live litigation assessment requires review of current federal dockets and FDA patent listings.

Settlement agreements, if any, should be evaluated for:

• Entry dates.
• Authorized-generic provisions.
• Supply or licensing obligations.
• Release of patent claims.
• Restrictions by strength or dosage form.
• Antitrust exposure.

For a mature paroxetine product, commercial settlement value is generally lower than for a first generic challenge to a high-revenue product with several years of remaining patent life.

How strong is the Pexeva patent estate?

The estate is weak as a current exclusivity platform but remains relevant for freedom-to-operate review. Its practical strength is limited by the age of the product, expiration of historical exclusivity, conventional dosage form, and generic availability.

Patent-estate factor	Assessment
New chemical entity protection	Expired
Salt-specific protection	Historical; commercial effect limited
Formulation complexity	Low to moderate
Manufacturing barriers	Potentially relevant but unlikely to block routine generic entry
Method-of-use protection	Limited practical value for an established antidepressant
Current generic barrier	Low
Licensing value	Primarily supply, formulation, or manufacturing related

Key Takeaways

• Pexeva is an immediate-release paroxetine mesylate tablet approved in four strengths.
• Its excipient system is conventional and centers on diluents, a binder, a superdisintegrant, lubricant, and film-coating materials.
• The primary formulation priorities are content uniformity, rapid dissolution, tablet robustness, and moisture control.
• Pexeva has no meaningful remaining original-drug exclusivity.
• Generic entry and price competition, rather than biosimilar competition, define the market.
• The strongest commercial opportunities are low-cost manufacturing, reliable API supply, co-processed excipient systems, global formulation flexibility, and selective patient-friendly dosage forms.
• Any new formulation must be screened against unexpired patents, FDA reference-product requirements, and bioequivalence expectations.
• Pexeva offers limited patent-driven licensing value but can support manufacturing, excipient, packaging, and supply agreements.

FAQs About Pexeva Excipient and Commercial Strategy

Can paroxetine mesylate be formulated with different excipients from Pexeva?

Yes. A generic product may use different inactive ingredients if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and labeling.

Is lactose-free Pexeva commercially feasible?

A lactose-free paroxetine mesylate tablet is technically feasible using alternative fillers such as microcrystalline cellulose, mannitol, dibasic calcium phosphate, or selected co-processed excipients. The formulation would require development work to confirm content uniformity, hardness, friability, and dissolution.

Can Pexeva be reformulated as an orally disintegrating tablet?

Yes, but an orally disintegrating formulation would require a separate development and regulatory strategy. Taste masking, dose uniformity, moisture sensitivity, and rapid disintegration would become central development issues.

Is paroxetine mesylate interchangeable with paroxetine hydrochloride?

Interchangeability depends on the specific FDA-approved product and its therapeutic-equivalence evaluation. The two salts contain the same active moiety but are not automatically interchangeable solely because they contain paroxetine.

Does Pexeva provide an opportunity for a 505(b)(2) product?

Potentially. A 505(b)(2) strategy could support a differentiated dosage form, delivery system, or administration route. The commercial case would depend on clinical utility, formulation differentiation, intellectual-property protection, and the ability to avoid direct price competition with generic tablets.

References

1. U.S. Food and Drug Administration. (2003). Pexeva (paroxetine mesylate) tablets, prescribing information. NDA 21-323.
2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. Center for Drug Evaluation and Research.
5. U.S. Food and Drug Administration. (2022). ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin: Guidance for industry.